Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Effect of a One-Year Consolidation Treatment with Ponatinib 15 mg on Treatment Free-Remission Rate in Patients with Philadelphia-Positive Chronic Myeloid Leukemia, who had previously Achieved a Deep Molecular Response with Imatinib

    Summary
    EudraCT number
    2017-004565-27
    Trial protocol
    ES  
    Global end of trial date
    29 Apr 2024

    Results information
    Results version number
    v1(current)
    This version publication date
    11 Apr 2025
    First version publication date
    11 Apr 2025
    Other versions
    Summary report(s)
    PonaZero_Resúmen Resultados

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    PonaZero_study
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    FUNDACIÓN TEÓFILO HERNANDO
    Sponsor organisation address
    Edificio las Rozas 23, planta S, oficina 1, Ctra. de La Coruña, km 23, 200, 28290 Las Rozas de Madr, Madrid, Spain, 28290
    Public contact
    Cecilia López García, FUNDACIÓN TEÓFILO HERNANDO, 0034 911923700, coordinacion.clinica@ifth.es
    Scientific contact
    Cecilia López García, FUNDACIÓN TEÓFILO HERNANDO, 0034 911923700, coordinacion.clinica@ifth.es
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    20 Aug 2024
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    07 Jun 2023
    Global end of trial reached?
    Yes
    Global end of trial date
    29 Apr 2024
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The primary objective is to evaluate the proportion of patients without confirmed loss of MR4 or loss of MMR (don’t require confirmation) within 48 weeks following ponatinib therapy cessation.
    Protection of trial subjects
    1. The protocol and the informed consent were review and approved by the IEC of the Hospital Universitario de la Princesa (10/10/2018) and the AEMPS (15/11/2018). 2. Patients gave informed consent before the study began. 3. The clinical trials was conducted in accordance with the Declaration of Helsinki, GCP, and applicable regulatory requirements 4. The CRAs in charge of the trial periodically monitored that the study was conducted in accordance with the protocol and verified the accuracy and completeness of the data recorded in the eCRFs. 5. All patient information in this clinical trial was handled with the highest level of confidentiality. Patients were assigned a unique coded identifier (XX-XX) instead of using personal names to ensure their anonymity. This coding system was applied to all study-related documentation, including eCRFs, laboratory reports, and study databases.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    25 Jun 2019
    Long term follow-up planned
    Yes
    Long term follow-up rationale
    Safety, Efficacy
    Long term follow-up duration
    2 Years
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Spain: 24
    Worldwide total number of subjects
    24
    EEA total number of subjects
    24
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    20
    From 65 to 84 years
    4
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Recruitment start date: 25/06/2019 Recruitment end date: 16/07/2021 Number of centers: 8 Patients recruited: 24 (center 2= 3; center 3= 1; center 4= 9; center 6= 1; center 8= 1, center 9= 4; center 10= 1; center 11= 4)

    Pre-assignment
    Screening details
    Number of subjects screened: 24 Number of screening failures: 1 did not meet the inclusion criteria (center 11)

    Period 1
    Period 1 title
    Consolidation phase (48 weeks)
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Arm title
    Single-arm
    Arm description
    Patients that received ponatinib 15 mg during the consolidation phase
    Arm type
    Experimental

    Investigational medicinal product name
    Ponatinib
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Film-coated tablet
    Routes of administration
    Oral use
    Dosage and administration details
    15 mg once daily

    Number of subjects in period 1 [1]
    Single-arm
    Started
    23
    Consolidation phase
    23
    Completed
    19
    Not completed
    4
         Adverse event, non-fatal
    3
         Protocol deviation
    1
    Notes
    [1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
    Justification: In total, 24 patients were enrolled and 23 were included in the study as 1 patients was a screening failure.
    Period 2
    Period 2 title
    Treatment-Free Remission (96 weeks)
    Is this the baseline period?
    No
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Arm title
    Single-arm
    Arm description
    -
    Arm type
    No intervention

    Investigational medicinal product name
    No investigational medicinal product assigned in this arm
    Number of subjects in period 2
    Single-arm
    Started
    19
    Completed
    13
    Not completed
    6
         Loss of molecular response
    6

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Consolidation phase (48 weeks)
    Reporting group description
    -

    Reporting group values
    Consolidation phase (48 weeks) Total
    Number of subjects
    23 23
    Age categorical
    Units: Subjects
        In utero
    0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0
        Newborns (0-27 days)
    0 0
        Infants and toddlers (28 days-23 months)
    0 0
        Children (2-11 years)
    0 0
        Adolescents (12-17 years)
    0 0
        Adults (18-64 years)
    19 19
        From 65-84 years
    4 4
        85 years and over
    0 0
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    52.8 ( 14.1 ) -
    Gender categorical
    Units: Subjects
        Female
    8 8
        Male
    15 15
    Race
    Units: Subjects
        Caucasian
    22 22
        Latin
    1 1
    ECOG
    Units: Subjects
        0-zero
    19 19
        1-one
    4 4
    Physical examination - General
    Units: Subjects
        Normal
    22 22
        Abnormal
    1 1
    Physical examination - Skin
    Units: Subjects
        Normal
    22 22
        Abnormal
    1 1
    Physical examination - Neck
    Units: Subjects
        Normal
    23 23
        Abnormal
    0 0
    Physical examination - Ears
    Units: Subjects
        Normal
    23 23
        Abnormal
    0 0
    Physical examination - Eyes
    Units: Subjects
        Normal
    22 22
        Abnormal
    1 1
    Physical examination - Nose
    Units: Subjects
        Normal
    23 23
        Abnormal
    0 0
    Physical examination - Heart
    Units: Subjects
        Normal
    23 23
        Abnormal
    0 0
    Physical examination - Throat
    Units: Subjects
        Normal
    23 23
        Abnormal
    0 0
    Physical examination - Lungs
    Units: Subjects
        Normal
    23 23
        Abnormal
    0 0
    Physical examination - Abdomen
    Units: Subjects
        Normal
    23 23
        Abnormal
    0 0
    Physical examination - Back
    Units: Subjects
        Normal
    23 23
        Abnormal
    0 0
    Physical examination - Lymph nodes
    Units: Subjects
        Normal
    23 23
        Abrnomal
    0 0
    Physical examination - Neurologic
    Units: Subjects
        Normal
    23 23
        Abnormal
    0 0
    Physical examination - Extremities
    Units: Subjects
        Normal
    23 23
        Abnormal
    0 0
    Physical examination - Vascular
    Units: Subjects
        Normal
    23 23
        Abnormal
    0 0
    Physical examination - Extramedular
    Units: Subjects
        Normal
    23 23
        Abnormal
    0 0
    Electrocardiogram
    Units: Subjects
        Normal
    22 22
        Abnormal
    1 1
    Echocardiogram
    Units: Subjects
        Normal
    21 21
        Abnormal
    2 2
    Pregnancy test
    Units: Subjects
        Negative
    3 3
        Not applicable
    20 20
    Hepatitis B surface antibody
    Units: Subjects
        Negative
    15 15
        Positive
    6 6
        No data
    2 2
    Hepatitis B surface antigen
    Units: Subjects
        Negative
    21 21
        Positive
    0 0
        No data
    2 2
    Hepatitis B core
    Units: Subjects
        Negative
    19 19
        Positive
    2 2
        No data
    2 2
    Height
    Units: cm
        arithmetic mean (standard deviation)
    167.4 ( 9.3 ) -
    Weight
    Units: kg
        arithmetic mean (standard deviation)
    76.5 ( 12.0 ) -
    BMI
    Units: kg/m2
        arithmetic mean (standard deviation)
    27.4 ( 4.6 ) -
    Temperature
    Units: celsius temperature
        arithmetic mean (standard deviation)
    36.0 ( 0.4 ) -
    Respiratory rate
    Units: breaths per minute
        arithmetic mean (standard deviation)
    16.1 ( 2.1 ) -
    Systolic blood pressure
    Units: mmHg
        arithmetic mean (standard deviation)
    130.1 ( 22.6 ) -
    Diastolic blood pressure
    Units: mmHg
        arithmetic mean (standard deviation)
    75.7 ( 12.9 ) -
    Pulse
    Units: lpm
        arithmetic mean (standard deviation)
    72.5 ( 10.7 ) -
    BCR-ABL molecular response
    Units: not applicable
        arithmetic mean (standard deviation)
    0.0016 ( 0.00 ) -
    Sokal risk
    Units: NA
        arithmetic mean (standard deviation)
    0.58 ( 0.3 ) -
    Hasford score
    Units: NA
        arithmetic mean (standard deviation)
    360.91 ( 351.6 ) -
    Eutos score
    Units: NA
        arithmetic mean (standard deviation)
    14.33 ( 17.4 ) -
    PR interval
    Units: ms
        arithmetic mean (standard deviation)
    144.6 ( 17.3 ) -
    QRS complex
    Units: ms
        arithmetic mean (standard deviation)
    98.9 ( 16.8 ) -
    QTcF interval
    Units: ms
        arithmetic mean (standard deviation)
    393.6 ( 63.4 ) -
    Heart rate
    Units: bpm
        arithmetic mean (standard deviation)
    69.0 ( 11.8 ) -
    RBC
    Units: x106/uL
        arithmetic mean (standard deviation)
    4.2 ( 0.5 ) -
    Hemoglobin
    Units: g/dL
        arithmetic mean (standard deviation)
    13.8 ( 1.3 ) -
    Hematocrit
    Units: percentage
        arithmetic mean (standard deviation)
    40.1 ( 4.1 ) -
    Platelets
    Units: x109
        arithmetic mean (standard deviation)
    235.5 ( 43.0 ) -
    Leucocytes
    Units: x109
        arithmetic mean (standard deviation)
    5.6 ( 1.6 ) -
    VCM
    Units: f/L
        arithmetic mean (standard deviation)
    95.0 ( 4.0 ) -
    Neutrophils absolute count
    Units: 109/L
        arithmetic mean (standard deviation)
    3.1 ( 1.1 ) -
    Neutrophils
    Units: percentage
        arithmetic mean (standard deviation)
    55.2 ( 8.7 ) -
    Lymphocytes
    Units: percentage
        arithmetic mean (standard deviation)
    32.4 ( 7.5 ) -
    Monocytes
    Units: percentage
        arithmetic mean (standard deviation)
    8.1 ( 1.9 ) -
    Eosinophils
    Units: percentage
        arithmetic mean (standard deviation)
    3.4 ( 2.4 ) -
    Basophils
    Units: percentage
        arithmetic mean (standard deviation)
    0.8 ( 0.4 ) -
    WBC
    Units: NA
        arithmetic mean (standard deviation)
    100.0 ( 0.2 ) -
    Glucose
    Units: mg/dL
        arithmetic mean (standard deviation)
    100.9 ( 9.9 ) -
    BUN
    Units: mg/dL
        arithmetic mean (standard deviation)
    32.4 ( 7.3 ) -
    Creatinine
    Units: mg/dL
        arithmetic mean (standard deviation)
    1.0 ( 0.2 ) -
    Albumin
    Units: g/dL
        arithmetic mean (standard deviation)
    5.9 ( 7.1 ) -
    AST
    Units: U/L
        arithmetic mean (standard deviation)
    21.9 ( 4.1 ) -
    ALT
    Units: U/L
        arithmetic mean (standard deviation)
    20.4 ( 8.4 ) -
    Alkaline phosphatase
    Units: UI/L
        arithmetic mean (standard deviation)
    68.8 ( 21.2 ) -
    Total billirubin
    Units: mg/dL
        arithmetic mean (standard deviation)
    0.5 ( 0.2 ) -
    Indirect billirubin
    Units: mg/dL
        arithmetic mean (standard deviation)
    0.5 ( 0.2 ) -
    Direct billirubin
    Units: mg/dL
        arithmetic mean (standard deviation)
    0.2 ( 0.1 ) -
    Troponin
    Units: ng/mL
        arithmetic mean (standard deviation)
    9.4 ( 5.9 ) -
    Troponin T
    Units: ng/mL
        arithmetic mean (standard deviation)
    10.3 ( 4.8 ) -
    NT-proBNP
    Units: pg/mL
        arithmetic mean (standard deviation)
    51.5 ( 57.5 ) -
    BNP
    Units: pg/mL
        arithmetic mean (standard deviation)
    113.8 ( 106.9 ) -
    Phosphorus
    Units: mg/dL
        arithmetic mean (standard deviation)
    2.7 ( 0.5 ) -
    Magnesium
    Units: mg/dL
        arithmetic mean (standard deviation)
    2.0 ( 0.1 ) -
    Soidum
    Units: mmol/L
        arithmetic mean (standard deviation)
    140.9 ( 2.0 ) -
    Potassium
    Units: mmol/L
        arithmetic mean (standard deviation)
    4.2 ( 0.3 ) -
    Calcium
    Units: mg/dL
        arithmetic mean (standard deviation)
    9.2 ( 0.4 ) -
    Amilase
    Units: U/L
        arithmetic mean (standard deviation)
    68.4 ( 25.2 ) -
    GGT
    Units: U/L
        arithmetic mean (standard deviation)
    20.6 ( 14.0 ) -
    LDH
    Units: U/L
        arithmetic mean (standard deviation)
    213.3 ( 46.3 ) -
    Lipase
    Units: U/L
        arithmetic mean (standard deviation)
    82.6 ( 72.1 ) -
    Total cholesterol
    Units: mg/dL
        arithmetic mean (standard deviation)
    175.7 ( 30.7 ) -
    Triglycerides
    Units: mg/dL
        arithmetic mean (standard deviation)
    113.7 ( 58.6 ) -
    HbA1c
    Units: percentage
        arithmetic mean (standard deviation)
    5.3 ( 0.3 ) -
    C-reactive protein
    Units: mg/dL
        arithmetic mean (standard deviation)
    0.3 ( 0.3 ) -
    Subject analysis sets

    Subject analysis set title
    TFR Phase Group
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Number of patients who entered ponatinib TFR phase

    Subject analysis set title
    Consolidation Phase Group
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Patients who entered the Ponatinib consolidation phase

    Subject analysis set title
    Safety analysis set
    Subject analysis set type
    Safety analysis
    Subject analysis set description
    All patients who received at least one dose of ponatinib

    Subject analysis set title
    Patients who restarted TKI
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Patients who lost molecular response and restart imatinib or any Tyrosine Kinase-Inhibitor treatment

    Subject analysis sets values
    TFR Phase Group Consolidation Phase Group Safety analysis set Patients who restarted TKI
    Number of subjects
    19
    23
    23
    5
    Age categorical
    Units: Subjects
        In utero
    0
    0
    0
    0
        Preterm newborn infants (gestational age < 37 wks)
    0
    0
    0
    0
        Newborns (0-27 days)
    0
    0
    0
    0
        Infants and toddlers (28 days-23 months)
    0
    0
    0
    0
        Children (2-11 years)
    0
    0
    0
    0
        Adolescents (12-17 years)
    0
    0
    0
    0
        Adults (18-64 years)
    18
    19
    19
    5
        From 65-84 years
    1
    4
    4
    0
        85 years and over
    0
    0
    0
    0
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Gender categorical
    Units: Subjects
        Female
        Male
    Race
    Units: Subjects
        Caucasian
        Latin
    ECOG
    Units: Subjects
        0-zero
        1-one
    Physical examination - General
    Units: Subjects
        Normal
        Abnormal
    Physical examination - Skin
    Units: Subjects
        Normal
        Abnormal
    Physical examination - Neck
    Units: Subjects
        Normal
        Abnormal
    Physical examination - Ears
    Units: Subjects
        Normal
        Abnormal
    Physical examination - Eyes
    Units: Subjects
        Normal
        Abnormal
    Physical examination - Nose
    Units: Subjects
        Normal
        Abnormal
    Physical examination - Heart
    Units: Subjects
        Normal
        Abnormal
    Physical examination - Throat
    Units: Subjects
        Normal
        Abnormal
    Physical examination - Lungs
    Units: Subjects
        Normal
        Abnormal
    Physical examination - Abdomen
    Units: Subjects
        Normal
        Abnormal
    Physical examination - Back
    Units: Subjects
        Normal
        Abnormal
    Physical examination - Lymph nodes
    Units: Subjects
        Normal
        Abrnomal
    Physical examination - Neurologic
    Units: Subjects
        Normal
        Abnormal
    Physical examination - Extremities
    Units: Subjects
        Normal
        Abnormal
    Physical examination - Vascular
    Units: Subjects
        Normal
        Abnormal
    Physical examination - Extramedular
    Units: Subjects
        Normal
        Abnormal
    Electrocardiogram
    Units: Subjects
        Normal
        Abnormal
    Echocardiogram
    Units: Subjects
        Normal
        Abnormal
    Pregnancy test
    Units: Subjects
        Negative
        Not applicable
    Hepatitis B surface antibody
    Units: Subjects
        Negative
        Positive
        No data
    Hepatitis B surface antigen
    Units: Subjects
        Negative
        Positive
        No data
    Hepatitis B core
    Units: Subjects
        Negative
        Positive
        No data
    Height
    Units: cm
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Weight
    Units: kg
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    BMI
    Units: kg/m2
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Temperature
    Units: celsius temperature
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Respiratory rate
    Units: breaths per minute
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Systolic blood pressure
    Units: mmHg
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Diastolic blood pressure
    Units: mmHg
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Pulse
    Units: lpm
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    BCR-ABL molecular response
    Units: not applicable
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Sokal risk
    Units: NA
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Hasford score
    Units: NA
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Eutos score
    Units: NA
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    PR interval
    Units: ms
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    QRS complex
    Units: ms
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    QTcF interval
    Units: ms
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Heart rate
    Units: bpm
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    RBC
    Units: x106/uL
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Hemoglobin
    Units: g/dL
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Hematocrit
    Units: percentage
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Platelets
    Units: x109
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Leucocytes
    Units: x109
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    VCM
    Units: f/L
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Neutrophils absolute count
    Units: 109/L
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Neutrophils
    Units: percentage
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Lymphocytes
    Units: percentage
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Monocytes
    Units: percentage
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Eosinophils
    Units: percentage
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Basophils
    Units: percentage
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    WBC
    Units: NA
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Glucose
    Units: mg/dL
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    BUN
    Units: mg/dL
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Creatinine
    Units: mg/dL
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Albumin
    Units: g/dL
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    AST
    Units: U/L
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    ALT
    Units: U/L
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Alkaline phosphatase
    Units: UI/L
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Total billirubin
    Units: mg/dL
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Indirect billirubin
    Units: mg/dL
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Direct billirubin
    Units: mg/dL
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Troponin
    Units: ng/mL
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Troponin T
    Units: ng/mL
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    NT-proBNP
    Units: pg/mL
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    BNP
    Units: pg/mL
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Phosphorus
    Units: mg/dL
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Magnesium
    Units: mg/dL
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Soidum
    Units: mmol/L
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Potassium
    Units: mmol/L
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Calcium
    Units: mg/dL
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Amilase
    Units: U/L
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    GGT
    Units: U/L
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    LDH
    Units: U/L
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Lipase
    Units: U/L
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Total cholesterol
    Units: mg/dL
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    Triglycerides
    Units: mg/dL
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    HbA1c
    Units: percentage
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    C-reactive protein
    Units: mg/dL
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Single-arm
    Reporting group description
    Patients that received ponatinib 15 mg during the consolidation phase
    Reporting group title
    Single-arm
    Reporting group description
    -

    Subject analysis set title
    TFR Phase Group
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Number of patients who entered ponatinib TFR phase

    Subject analysis set title
    Consolidation Phase Group
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Patients who entered the Ponatinib consolidation phase

    Subject analysis set title
    Safety analysis set
    Subject analysis set type
    Safety analysis
    Subject analysis set description
    All patients who received at least one dose of ponatinib

    Subject analysis set title
    Patients who restarted TKI
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Patients who lost molecular response and restart imatinib or any Tyrosine Kinase-Inhibitor treatment

    Primary: Proportion of patients without confirmed loss of MR4 or MMR within 48 weeks after ponatinib TFR

    Close Top of page
    End point title
    Proportion of patients without confirmed loss of MR4 or MMR within 48 weeks after ponatinib TFR
    End point description
    The primary efficacy variable was the binary outcome measure, the proportion of patients without confirmed loss of MR4 or loss of MMR within 48 weeks of ponatinib TFR. This variable was defined as the number of patients with no documented confirmed loss of MR4 or no loss of MMR and no restart of imatinib therapy in the first 48 weeks after the start of the ponatinib TFR phase divided by the number of patients who entered the ponatinib TFR phase (full analysis set).
    End point type
    Primary
    End point timeframe
    From ponatinib discontinuation until 48 weeks of follow-up in TFR phase.
    End point values
    Single-arm TFR Phase Group
    Number of subjects analysed
    19
    19
    Units: Proportion
        Without loss of molecular response
    13
    13
        Loss of molecular response
    6
    6
    Statistical analysis title
    Primary endpoint analysis
    Statistical analysis description
    Primary Endpoint Analysis: Proportion of Patients Maintaining MR4/MMR at 48 Weeks Post-Ponatinib TFR
    Comparison groups
    Single-arm v TFR Phase Group
    Number of subjects included in analysis
    38
    Analysis specification
    Pre-specified
    Analysis type
    other [1]
    P-value
    < 0.05 [2]
    Method
    Clopper-Pearson exact CI
    Parameter type
    Clopper-Pearson exact CI
    Point estimate
    0.684
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.434
         upper limit
    0.874
    Notes
    [1] - Single-arm proportion analysis with Clopper-Pearson CI. IMPORTANT NOTE: This analysis was performed in the group of the patients who entered the TFR phase only (n=19).
    [2] - Exact Clopper-Pearson confidence interval was used to assess the proportion of patients maintaining MR4/MMR at 48 weeks in TFR phase. The null hypothesis was rejected if the lower limit of the 95% confidence interval was greater than 0.10 (10%).

    Secondary: Proportion of patients without documented loss of MR4 or loss of MMR at 72 and 96 weeks after ponatinib discontinuation

    Close Top of page
    End point title
    Proportion of patients without documented loss of MR4 or loss of MMR at 72 and 96 weeks after ponatinib discontinuation
    End point description
    Proportion of patients without documented loss of MR4 or loss of MMR at 72 and 96 weeks after discontinuation of ponatinib treatment. This proportion of patients was calculated by dividing the number of patients with no documented confirmed loss of MR4 or loss of MMR and no reinitiation of imatinib at 72 or 96 weeks after discontinuation of ponatinib by the number of patients who entered the ponatinib TFR phase (full analysis set).
    End point type
    Secondary
    End point timeframe
    From ponatinib discontinuation until 72 and 96 weeks of follow-up in TFR phase.
    End point values
    Single-arm TFR Phase Group
    Number of subjects analysed
    19 [3]
    19
    Units: Proportion
        Without loss of molecular response
    13
    13
        Loss molecular response
    6
    6
    Notes
    [3] - The number of patients who entered the TFR phase is 19.
    Statistical analysis title
    Analysis of TFR at 72 and 76 weeks
    Statistical analysis description
    Analysis of Treatment-Free Remission (TFR) at 72 and 96 Weeks (visit 24 and 25, respectively)
    Comparison groups
    Single-arm v TFR Phase Group
    Number of subjects included in analysis
    38
    Analysis specification
    Pre-specified
    Analysis type
    other [4]
    P-value
    < 0.05
    Method
    Clopper-Pearson exact CI
    Parameter type
    Clopper-Pearson exact CI
    Point estimate
    0.68
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.43
         upper limit
    0.87
    Notes
    [4] - Single-arm proportion analysis with Clopper-Pearson CI

    Secondary: Progression-Free Survival (PFS) after ponatinib discontinuation

    Close Top of page
    End point title
    Progression-Free Survival (PFS) after ponatinib discontinuation
    End point description
    Progression free survival (PFS): Estimation of PFS after discontinuation of ponatinib was calculated using the Kaplan-Meier (KM) method. PFS was measured from the date of discontinuation of ponatinib therapy to the date of the earliest of the following events: progression to AP/BC or death from any cause. For patients who are not known to have progressed or died on or before the cut-off date for the KM analysis, the PFS interval is right censored to the date of the last assessment of molecular response status or the cut-off date, whichever is earlier.
    End point type
    Secondary
    End point timeframe
    From ponatinib discontinuation until progression to AP/BC, death, or last molecular response assessment before data cut-off
    End point values
    TFR Phase Group
    Number of subjects analysed
    19
    Units: Number of patients
    19
    No statistical analyses for this end point

    Secondary: Treatment-Free Survival (TFS) after ponatinib discontinuation

    Close Top of page
    End point title
    Treatment-Free Survival (TFS) after ponatinib discontinuation
    End point description
    End point type
    Secondary
    End point timeframe
    From ponatinib discontinuation until loss of MMR, confirmed loss of MR4, restart of imatinib, progression to AP/BC, or death from any cause.
    End point values
    Single-arm TFR Phase Group
    Number of subjects analysed
    19
    19
    Units: Number of patients
    15
    15
    Statistical analysis title
    Kaplan-Meier Estimation of TFS
    Comparison groups
    Single-arm v TFR Phase Group
    Number of subjects included in analysis
    38
    Analysis specification
    Pre-specified
    Analysis type
    other [5]
    P-value
    < 0.05
    Method
    Kaplan-Meier survival analysis
    Parameter type
    Kaplan-Meier survival analysis
    Point estimate
    68.4
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    50.4
         upper limit
    92.9
    Notes
    [5] - Kaplan-Meier survival analysis

    Secondary: Overall Survival (OS) after ponatinib discontinuation

    Close Top of page
    End point title
    Overall Survival (OS) after ponatinib discontinuation
    End point description
    Overall survival (OS): OS was defined as the time from the date of discontinuation of ponatinib therapy to the date of death from any cause. If a patient was not known to have died, OS was censored at the date of last contact (Figure 2). A similar method of analysis was used to estimate the time to regain MR4 from the date of restart of imatinib treatment.
    End point type
    Secondary
    End point timeframe
    From ponatinib discontinuation until death from any cause or last patient contact (censored)
    End point values
    TFR Phase Group
    Number of subjects analysed
    19
    Units: Number of patients
    19
    No statistical analyses for this end point

    Secondary: Proportion of patients who regained MR4 within 48 weeks after imatinib re-initiation

    Close Top of page
    End point title
    Proportion of patients who regained MR4 within 48 weeks after imatinib re-initiation
    End point description
    The proportion of patients who regained MR4 within 48 weeks of imatinib treatment re- initiation following confirmed loss of MR4 or loss of MMR in the first 48 weeks subsequent to ponatinib cessation, was calculated by dividing the number of patients who re-achieve MR4 within 48 weeks of imatinib treatment re-initiation, following confirmed loss of MR4 or loss of MMR in the first 48 weeks subsequent to ponatinib cessation, by the number of patients who ceased ponatinib therapy and subsequently had confirmed loss of MR4 or lost MMR in the first 48 weeks following ponatinib cessation and re-initiated imatinib treatment. In the calculation of this proportion, patients who dropped out early without regaining MR4 during the re-treatment period were considered to be unsuccessful reinductions of MR4 and were counted in the denominator in the calculation of the rate.
    End point type
    Secondary
    End point timeframe
    From imatinib re-initiation until 48 weeks of follow-up
    End point values
    Patients who restarted TKI
    Number of subjects analysed
    5
    Units: Proportion
        Regain molecular response
    4
        Not regain molecular response
    1
    No statistical analyses for this end point

    Other pre-specified: Plasma Concentration of Ponatinib Over Time

    Close Top of page
    End point title
    Plasma Concentration of Ponatinib Over Time
    End point description
    End point type
    Other pre-specified
    End point timeframe
    rom Day 0 of Ponatinib Consolidation Phase until TFR Visit 11 (Day 28 of Cycle 1 in TFR phase)
    End point values
    Consolidation Phase Group
    Number of subjects analysed
    17 [6]
    Units: ng/mL
        median (inter-quartile range (Q1-Q3))
    15.205 (10.030 to 20.431)
    Notes
    [6] - Number of patients at the visit 10 . Day 336 (end of treatment)
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From first ponatinib dose until study completion, categorized by phase: Consolidation phase, TFR phase, and Imatinib restart phase
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    26.0
    Reporting groups
    Reporting group title
    Consolidation phase
    Reporting group description
    AEs reported during the consolidation phase

    Reporting group title
    TFR phase
    Reporting group description
    AEs reported during TFR

    Reporting group title
    Imatinib restart
    Reporting group description
    AEs reported during imatinib restart period

    Serious adverse events
    Consolidation phase TFR phase Imatinib restart
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 23 (0.00%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         number of deaths (all causes)
    0
    0
    0
         number of deaths resulting from adverse events
    0
    0
    0
    Frequency threshold for reporting non-serious adverse events: 0%
    Non-serious adverse events
    Consolidation phase TFR phase Imatinib restart
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    23 / 23 (100.00%)
    19 / 19 (100.00%)
    1 / 5 (20.00%)
    Vascular disorders
    Essential hypertension
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    2
    0
    0
    Hypertension
         subjects affected / exposed
    2 / 23 (8.70%)
    1 / 19 (5.26%)
    0 / 5 (0.00%)
         occurrences all number
    2
    2
    0
    Intermittent claudication
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Superficial thrombophlebitis
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Surgical and medical procedures
    Tooth extraction
         subjects affected / exposed
    1 / 23 (4.35%)
    1 / 19 (5.26%)
    0 / 5 (0.00%)
         occurrences all number
    1
    1
    0
    General disorders and administration site conditions
    Asthenia
         subjects affected / exposed
    6 / 23 (26.09%)
    0 / 19 (0.00%)
    1 / 5 (20.00%)
         occurrences all number
    8
    0
    2
    Chills
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Decreased appetite
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Feeling cold
         subjects affected / exposed
    0 / 23 (0.00%)
    1 / 19 (5.26%)
    0 / 5 (0.00%)
         occurrences all number
    0
    1
    0
    Inflammation localized
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Influenza-like illness
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Malaise
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    1 / 5 (20.00%)
         occurrences all number
    1
    0
    1
    Pyrexia
         subjects affected / exposed
    2 / 23 (8.70%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    2
    0
    0
    Secretion discharge
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    0
    0
    0
    Immune system disorders
    Seasonal allergy
         subjects affected / exposed
    0 / 23 (0.00%)
    1 / 19 (5.26%)
    0 / 5 (0.00%)
         occurrences all number
    0
    1
    0
    Reproductive system and breast disorders
    Erectile dysfunction
         subjects affected / exposed
    2 / 23 (8.70%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    2
    0
    0
    Nipple pain
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Respiratory, thoracic and mediastinal disorders
    Asthma
         subjects affected / exposed
    0 / 23 (0.00%)
    1 / 19 (5.26%)
    0 / 5 (0.00%)
         occurrences all number
    0
    1
    0
    Dysphonia
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Oropharyngeal pain
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Pharyngitis
         subjects affected / exposed
    0 / 23 (0.00%)
    1 / 19 (5.26%)
    0 / 5 (0.00%)
         occurrences all number
    0
    1
    0
    Tonsillitis
         subjects affected / exposed
    0 / 23 (0.00%)
    1 / 19 (5.26%)
    0 / 5 (0.00%)
         occurrences all number
    0
    1
    0
    Voice alteration
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Psychiatric disorders
    Insomnia
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Sleep disorder
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Investigations
    Blood iron increased
         subjects affected / exposed
    0 / 23 (0.00%)
    0 / 19 (0.00%)
    1 / 5 (20.00%)
         occurrences all number
    0
    0
    1
    Blood urinc acid increased
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Hyperuricemia
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Serum amylase increased
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Serum lipase increased
         subjects affected / exposed
    2 / 23 (8.70%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    2
    0
    0
    Injury, poisoning and procedural complications
    Fall
         subjects affected / exposed
    0 / 23 (0.00%)
    1 / 19 (5.26%)
    0 / 5 (0.00%)
         occurrences all number
    0
    1
    0
    Injection site inflammation
         subjects affected / exposed
    0 / 23 (0.00%)
    1 / 19 (5.26%)
    0 / 5 (0.00%)
         occurrences all number
    0
    1
    0
    Subarachonoid hemorrhage
         subjects affected / exposed
    0 / 23 (0.00%)
    0 / 19 (0.00%)
    1 / 5 (20.00%)
         occurrences all number
    0
    0
    1
    Traumatic pneumothorax
         subjects affected / exposed
    0 / 23 (0.00%)
    0 / 19 (0.00%)
    1 / 5 (20.00%)
         occurrences all number
    0
    0
    1
    Cardiac disorders
    Tachycardia
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Nervous system disorders
    Dizziness postural
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Gait disturbance
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Headache
         subjects affected / exposed
    3 / 23 (13.04%)
    2 / 19 (10.53%)
    0 / 5 (0.00%)
         occurrences all number
    4
    4
    0
    Paresthesia
         subjects affected / exposed
    0 / 23 (0.00%)
    1 / 19 (5.26%)
    0 / 5 (0.00%)
         occurrences all number
    0
    1
    0
    Sensory disturbance
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Blood and lymphatic system disorders
    Anemia
         subjects affected / exposed
    0 / 23 (0.00%)
    1 / 19 (5.26%)
    1 / 5 (20.00%)
         occurrences all number
    0
    1
    1
    Leukocytosis
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Monocytosis
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    2
    0
    0
    Neutrophilia
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Eye disorders
    Dry eye
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Vision blurred
         subjects affected / exposed
    2 / 23 (8.70%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    3
    0
    0
    Gastrointestinal disorders
    Abdominal pain upper
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    2
    0
    0
    Anal fissure
         subjects affected / exposed
    2 / 23 (8.70%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    2
    0
    0
    Colitis
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Constipation
         subjects affected / exposed
    8 / 23 (34.78%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    8
    0
    0
    Diarrhea
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Diverticulosis
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Gastroesophageal reflux disease
         subjects affected / exposed
    0 / 23 (0.00%)
    0 / 19 (0.00%)
    1 / 5 (20.00%)
         occurrences all number
    0
    0
    1
    Haemorrhoids
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Heartburn
         subjects affected / exposed
    0 / 23 (0.00%)
    1 / 19 (5.26%)
    1 / 5 (20.00%)
         occurrences all number
    0
    1
    1
    Ileal ulcer
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Mouth ulceration
         subjects affected / exposed
    0 / 23 (0.00%)
    0 / 19 (0.00%)
    1 / 5 (20.00%)
         occurrences all number
    0
    0
    1
    Nausea
         subjects affected / exposed
    0 / 23 (0.00%)
    0 / 19 (0.00%)
    1 / 5 (20.00%)
         occurrences all number
    0
    0
    1
    Periodontal disease
         subjects affected / exposed
    0 / 23 (0.00%)
    1 / 19 (5.26%)
    0 / 5 (0.00%)
         occurrences all number
    0
    1
    0
    Skin and subcutaneous tissue disorders
    Dry skin
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Pemphigoid
         subjects affected / exposed
    0 / 23 (0.00%)
    1 / 19 (5.26%)
    0 / 5 (0.00%)
         occurrences all number
    0
    1
    0
    Pruritus
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Rash
         subjects affected / exposed
    5 / 23 (21.74%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    6
    0
    0
    Endocrine disorders
    Diabetes mellitus
         subjects affected / exposed
    0 / 23 (0.00%)
    1 / 19 (5.26%)
    0 / 5 (0.00%)
         occurrences all number
    0
    1
    0
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    3 / 23 (13.04%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    3
    0
    0
    Back pain
         subjects affected / exposed
    2 / 23 (8.70%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    2
    0
    0
    Bone pain
         subjects affected / exposed
    3 / 23 (13.04%)
    1 / 19 (5.26%)
    0 / 5 (0.00%)
         occurrences all number
    3
    1
    0
    Bursitis
         subjects affected / exposed
    0 / 23 (0.00%)
    1 / 19 (5.26%)
    0 / 5 (0.00%)
         occurrences all number
    0
    1
    0
    Fracture
         subjects affected / exposed
    0 / 23 (0.00%)
    0 / 19 (0.00%)
    1 / 5 (20.00%)
         occurrences all number
    0
    0
    1
    Heaviness in extremities
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Intervertebral disc disorder
         subjects affected / exposed
    2 / 23 (8.70%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    2
    0
    0
    Knee pain
         subjects affected / exposed
    0 / 23 (0.00%)
    1 / 19 (5.26%)
    0 / 5 (0.00%)
         occurrences all number
    0
    1
    0
    Lumbar pain
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    1 / 5 (20.00%)
         occurrences all number
    1
    0
    1
    Muscular weakness
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Myalgia
         subjects affected / exposed
    6 / 23 (26.09%)
    1 / 19 (5.26%)
    0 / 5 (0.00%)
         occurrences all number
    6
    1
    0
    Rib fracture
         subjects affected / exposed
    0 / 23 (0.00%)
    0 / 19 (0.00%)
    1 / 5 (20.00%)
         occurrences all number
    0
    0
    1
    Shoulder pain
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Spinal osteoarthritis
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Infections and infestations
    COVID-19
         subjects affected / exposed
    2 / 23 (8.70%)
    4 / 19 (21.05%)
    0 / 5 (0.00%)
         occurrences all number
    2
    4
    0
    Common cold
         subjects affected / exposed
    0 / 23 (0.00%)
    1 / 19 (5.26%)
    0 / 5 (0.00%)
         occurrences all number
    0
    1
    0
    Localised infection
         subjects affected / exposed
    0 / 23 (0.00%)
    0 / 19 (0.00%)
    1 / 5 (20.00%)
         occurrences all number
    0
    0
    1
    Oral infection
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Upper respiratory tract infection
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Urinary tract infection
         subjects affected / exposed
    0 / 23 (0.00%)
    0 / 19 (0.00%)
    1 / 5 (20.00%)
         occurrences all number
    0
    0
    1
    Metabolism and nutrition disorders
    Dyslipidaemia
         subjects affected / exposed
    0 / 23 (0.00%)
    1 / 19 (5.26%)
    0 / 5 (0.00%)
         occurrences all number
    0
    1
    0
    Hypercholesterolemia
         subjects affected / exposed
    3 / 23 (13.04%)
    1 / 19 (5.26%)
    0 / 5 (0.00%)
         occurrences all number
    3
    2
    0
    Hypertriglyceridemia
         subjects affected / exposed
    1 / 23 (4.35%)
    1 / 19 (5.26%)
    0 / 5 (0.00%)
         occurrences all number
    1
    3
    0
    Hypomagnesemia
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0
    Spinal flattening
         subjects affected / exposed
    1 / 23 (4.35%)
    0 / 19 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    05 Apr 2019
    - An error was found in the calculation of the total number of weeks with and without treatment with the study medication (being 28-day cycles, the correct number is 48 weeks per year instead of 52) that affects the primary and secondary objectives. - Discrepancies found between the study calendar tables and the protocol text. -Update of CTCAE from version 4.03 to 5.0 (has been released and will be used for the study).

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    The study had a small sample size (23 patients), limiting generalizability. The single-arm design prevents direct comparisons with alternative treatment discontinuation strategies. The maximum follow-up was 96 weeks, which may not be sufficient.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 15:29:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA